Third Harmonic Bio Inc. is a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and inflammation. The company's principal candidate includes THB001, is a highly selective, oral small-molecule inhibitor of KIT. Third Harmonic Bio Inc. is based in CAMBRIDGE, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-30.82M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.66 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -6.22% |
| Return on Assets (Trailing 12 Months) | -6.03% |
| Current Ratio (Most Recent Fiscal Quarter) | 50.28 |
| Quick Ratio (Most Recent Fiscal Quarter) | 50.29 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.67 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.17 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.78 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.61 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 40.76M |
| Free Float | 38.80M |
| Market Capitalization | $450.36M |
| Average Volume (Last 20 Days) | 0.22M |
| Beta (Past 60 Months) | 3.53 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 93.95% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |